Biblio
Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS. Leuk Res. 2021;110:106713.
Ibrutinib for Chronic Graft-Versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. Biol Blood Marrow Transplant. 2019.
Mutation Clearance after Transplantation for Myelodysplastic Syndrome. N Engl J Med. 2018;379(11):1028-1041.
Patient-reported treatment response in chronic graft--host disease. Haematologica. 2023.